Patent · US Active

Use of the CD2 signaling domain in second-generation chimeric antigen receptors

US10501519B2 · kind B2 · utility

3Cited by

26References

3Claims

0Family size

Assignee

The Trustees of the University of Pennsylvania · US

Inventors

Carl H. June · Yeadon, US
John Scholler · Narberth, US
Avery D. Posey · Philadelphia, US

Key dates

Filing date	Aug 4, 2017
Grant date	Dec 10, 2019
Priority date	—
Expiry date	Aug 4, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/02
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell expressing a CAR having an antigen binding domain, a transmembrane domain, a CD2 signaling domain, and a CD3 zeta signaling domain. The invention also includes incorporating CD2 into the CAR to alter the cytokine production of CAR-T cells in both negative and positive directions.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.